Welcome to our dedicated page for Plexus SEC filings (Ticker: PLXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Plexus Corp (NASDAQ: PLXS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Plexus files periodic and current reports as a Wisconsin corporation with Commission File Number 001-14423.
Among the key documents available are current reports on Form 8-K, which Plexus uses to furnish press releases announcing quarterly and annual financial results. These filings typically include information on revenue, operating margin, earnings per share, non-GAAP performance measures, return on invested capital, free cash flow and other financial metrics, as well as commentary on business conditions and program wins.
Through this page, users can track how Plexus reports its results for fiscal quarters and years, including references to its geographic segments in the Americas, Asia-Pacific and Europe, Middle East and Africa regions, and its focus on Aerospace/Defense, Healthcare/Life Sciences and Industrial market sectors. Filings also confirm corporate details such as state of incorporation and principal corporate location.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand the implications of each report. Real-time updates from the SEC’s EDGAR system, along with structured access to forms such as 8-K and other periodic reports, make it easier to review Plexus’ regulatory history and monitor ongoing disclosures related to PLXS.
Plexus Corp President & CEO Todd P. Kelsey reported multiple stock transactions. On February 18, 2026, he sold a total of 5,231 shares of common stock in open-market trades at prices around $194.47, $195.59, and $196.36. A footnote states these sales were made under a Rule 10b5-1 trading plan adopted on November 20, 2025.
Following these sales, he continued to hold tens of thousands of Plexus common shares directly. On February 17, 2026, he was granted 5,576 Performance Stock Units and also exercised 18,726 PSUs, receiving the same number of common shares. Separately, 8,802 shares were withheld to cover tax obligations related to the award.
Plexus Corp. reported the results of its 2026 Annual Meeting of Shareholders held on February 18, 2026. Shareholders elected all 10 director nominees, each receiving about 24 million votes in favor plus 1,032,978 broker non-votes.
Shareholders approved, on an advisory basis, the compensation of Plexus named executive officers, with 21,498,630 votes for, 2,207,349 against, 963,489 abstentions, and 1,032,978 broker non-votes. They also ratified PricewaterhouseCoopers LLP as independent auditors for fiscal 2026 with 24,258,094 votes for, 1,427,553 against, and 16,799 abstentions.
Plexus Corp. (PLXS) insider sale reported. The filing shows a sale by Todd P. Kelsey of 8,120 common shares on 02/03/2026 for $1,669,880.18.
The filing also lists vesting of 9,161 restricted stock units on 01/31/2025 and 570 performance stock units on 02/11/2025 recorded as compensation.
PLXS reported insider resale activity via Rule 144 notices. The filing lists restricted stock awards dated 01/22/2021, 01/25/2024, and 01/31/2025 with quantities 2,648, 3,450, and 3,443 respectively. It also records two reported sales by Oliver Mihm: 2,226 shares on 02/17/2026 and 2,327 shares on 11/25/2025, with corresponding proceeds shown.
Plexus Corp. insider OLIVER has filed a Form 144 indicating an intention to sell 2,226 shares of common stock. The planned sale is to be executed through Morgan Stanley Smith Barney LLC on NASDAQ, with an approximate sale date of 02/17/2026 and an aggregate market value of 442,495.41.
The 2,226 shares were acquired on 02/11/2025 as performance shares directly from the issuer. Plexus had 26,786,466 shares outstanding at the time referenced. In the past three months, OLIVER also sold 2,327 common shares on 11/25/2025 for gross proceeds of 333,179.86.
Plexus Corp. executive Patrick J. Jermain, Exec. VP & CFO, reported multiple equity transactions in Plexus Corp. (PLXS). On 02/12/2026, he completed an open-market sale of 2,321 shares of common stock at $201.1229 per share, leaving 14,561 directly held shares afterward.
On 02/17/2026, 5,611 Performance Stock Units were exercised/converted into common stock, increasing his direct holdings to 20,172 shares. In a separate tax-related move that same day, 2,638 shares were disposed of at $195.95 to cover tax obligations, resulting in 17,534 directly held shares.
The filing also shows 3,751 shares of common stock held indirectly in the Plexus Corp. 401(k) Retirement Plan. A footnote explains that, based on company performance over a three-year period, 142.4% of the portion of fiscal 2023 Performance Stock Units tied to relative total shareholder return vested, versus a maximum opportunity of up to 150%.
Plexus Corp regional president Frank Zycinski sold his remaining common shares in an open-market trade. On 02/12/2026 he sold 1,399 shares of Plexus common stock at a weighted average price of $205.9925 per share, leaving him with 0 shares beneficially owned directly.
The sales were executed in multiple trades at prices ranging from $205.96 to $205.995 per share, with the reported figure reflecting the weighted average sale price.
Plexus Corp. has a new significant institutional holder. A regulatory disclosure shows that American Century Investment Management, American Century Companies, and the Stowers Institute for Medical Research together beneficially own 1,560,622 shares of Plexus common stock, representing 5.8% of the outstanding class as of December 31, 2025.
The group reports sole voting power over 1,426,523 shares and sole dispositive power over 1,560,622 shares. They state that the shares were acquired and are held in the ordinary course of business, not to change or influence control of Plexus.
Plexus Corp. insider plans additional stock sale under Rule 144. A holder intends to sell 2,321 shares of Plexus common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $466,806.25 and 26,786,466 shares outstanding as of the notice.
The shares to be sold were acquired as performance shares from the issuer on 02/11/2025. The filing also lists prior sales by Patrick Jermain over the past three months, including 3,587 and 4,841 common shares sold on 02/04/2026 and 02/03/2026, respectively, with gross proceeds of $732,070.83 and $987,612.41.
A shareholder of PLXS filed a Rule 144 notice to sell 1,399 shares of common stock through Morgan Stanley Smith Barney LLC on 02/12/2026 on the NASDAQ, with an aggregate market value of $288,183.51 and 26,786,466 shares outstanding.
The shares to be sold were acquired as restricted stock from the issuer, including 676 shares acquired on 01/30/2026 and additional blocks of 165 and 558 shares acquired on 01/31/2025, all listed as fully paid in cash-equivalent terms.